CD8+ T cells of Tc2 phenotype mediate a GVL effect and prevent marrow rejection

Vox Sanguinis

Volumn 74, Issue SUPPL. 2, 1998, Pages 331-340

  Fowler, Daniel H ^a,b   Gress, R E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN;

ALLOGENIC BONE MARROW TRANSPLANTATION; CONFERENCE PAPER; GRAFT REJECTION; GRAFT VERSUS LEUKEMIA EFFECT; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0031821957     PISSN: 00429007     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1423-0410.1998.tb05439.x     Document Type: Conference Paper

References (60)

1. Martin, P. J., J. A. Hansen, C. D. Buckner, J. E. Sanders, H. J. Deeg, P. Stewart, F. R. Appelbaum, R. Clift, A. Fefer, and R. P. Witherspoon. 1985. Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood, 66:664-672.
2. Poynton, C. H. 1988. T cell depletion in bone marrow transplantation. Bone Marrow Transplant. 3:265-279.
3. Kolb, H. J., J. Mittermuller, C. Clemm, E. Holler, G. Ledderose, G. Brehm, M. Heim, and W. Wilmanns. 1990. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 76:2462-2465.
4. Bonini, C., G. Ferrari, S. Verzeletti, P. Servida, E. Zappone, L. Ruggieri, M. Ponzoni, S. Rossini, F. Mavilio, C. Traversari, and C. Bordignon. 1997. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia [see comments]. Science 276:1719-1724.
5. Champlin, R, J. Jansen, W. Ho, J. Gajewski, S. Nimer, K. Lee, M. Territo, D. Winston, G. Tricot, and T. Reichert. 1991. Retention of graft-versus-leukemia using selective depletion of CDS-positive T lymphocytes for prevention of graft-versus-host disease following bone marrow transplantation for chronic myelogenous leukemia. Transplant. Proc. 23:1695-1696.
6. Mosmann, T. R., and R. L. Coffman. 1989. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu.Rev.Immunol. 7:145-173.
7. + T cells secreting Th1 or Th2 cytokines. Immunity. 2:271-279.
8. Mosmann, T. R., H. Cherwinski, M. W. Bond, M. A. Giedlin, and R. L. Coffman. 1986. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J.Immunol. 136:2348-2357.
9. Oswald, I. P., R. T. Gazzinelli, A. Sher, and S. L. James. 1992. IL-10 synergizes with IL-4 and transforming growth factor-beta to inhibit macrophage cytotoxic activity. J.Immunol. 148:3578-3582.
10. Mosmann, T. R., and K. W. Moore. 1991. The role of IL-10 in crossregulation of TH1 and TH2 responses. Immunol Today. 12:A49-α53.
11. Sher, A., R. T. Gazzinelli, I. P. Oswald, M. Clerici, M. Kullberg, E. J. Pearce, J. A. Berzofsky, T. R. Mosmann, S. L. James, H. C. Morse, and G. M. Shearer. 1992. Role of T-cell derived cytokines in the downregulation of immune responses in parasitic and retroviral infection. Immunol.Rev. 127:183-204.
12. Del Prete, G., E. Maggi, and S. Romagnani. 1994. Human Th1 and Th2 cells: functional properties, mechanisms of regulation, and role in disease. Lab.Invest. 70:299-306.
13. Clerici, M., and G. M. Shearer. 1993. A TH1 ->TH2 switch is a critical step in the etiology of HIV infection [see comments]. Immunol.Today. 14:107-111.
14. Yamamura, M., K. Uyemura, R. J. Deans, K. Weinberg, T. H. Rea, B. R. Bloom, and R. L. Modlin. 1991. Defining protective responses to pathogens: cytokine profiles in leprosy lesions [published erratum appears in Science 1992 Jan 3;255[5040]:12]. Science 254:277-279.
15. Croft, M., L, Carter, S. L. Swain, and R. W. Dutton. 1994. Generation of polarized antigen-specific CDS effector populations: reciprocal action of interleukin [IL]-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles. J.Exp.Med. 180:1715-1728.
16. Henkart, P. A. 1994. Lymphocyte-Mediated Cytotoxicity: Two Pathways and Multiple Effector Molecules. Immunity 1:343-346.
17. Carter, L. L., and R. W. Dutton. 1995. Relative perform- and Fas-mediated lysis in T1 and T2 CDS effector populations. J Immunol 155:1028-1031.
18. Via, C. S., V. Rus, M. K. Gately, and F. D. Finkelman. 1994. IL-12 stimulates the development of acute graft-versus-host disease in mice that normally would develop chronic, autoimmune graft-versus-host disease. J.Immunol. 153:4040-4047.
19. Ferrara, J. L., S. Abhyankar, and D. G. Gilliland. 1993. Cytokine storm of graft-versus-host disease: a critical effector role for interleukin-1. Transplant. Proc. 25:1216-1217.
20. Via, C. S., and F. D. Finkelman. 1993. Critical role of interleukin-2 in the development of acute graft-versus-host disease. Int.Immunol 5:565-572.
21. Schwarer, A. P., Y. Z. Jiang, P. A. Brookes, A. J. Barren, J. R. Batchelor, J. M. Goldman, and R. I. Lechler. 1994. Frequency of anti-recipient alloreactive helper T-cell precursors in donor blood and graft-vers us-host disease after HLA-identical sibling bone-marrow transplantation. Lancet 341:203-205.
22. Theobald, M., T. Nierle, D. Bunjes, R. Arnold, and H. Heimpel. 1992. Host-specific interleukin-2-secreting donor T-cell precursors as predictors of acute graft-versus-host disease in bone marrow transplantation between HLA-identical siblings [see comments]. N.Engl.J.Med. 327:1613-1617.
23. Anasetti, C., J. A. Hansen, T. A. Waldmann, F. R. Appelbaum, J. Davis, H. J. Deeg, K. Doney, P. J. Martin, R. Nash, and R. Storb, 1994. Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. Blood. 84:1320-1327.
24. Knobloch, C., and G. Dennert. 1988. Asialo-GM1-positive T killer cells are generated in F1 mice injected with parental spleen cells. J.Immunol. 140:744-749.
25. Korngold, R. 1993. Biology of graft-vs.-host disease. Am.J.Pediatr.Hematol.Oncol. 15:18-27.
26. Hakim, F. T., S. O. Sharrow, S. Payne, and G. M. Shearer. 1991. Repopulation of host lymphohematopoietic systems by donor cells during graft-versus-host reaction in uni radiated adult F1 mice injected with parental lymphocytes. J.Immunol 146:2108-2115.
27. + cells in patients with graft-versus-host disease after allogeneic bone marrow transplantation. Bone.Marrow.Transplant. 13:181-185.
28. Roy, J., J. L. Platt, and D. J. Weisdorf. 1993. The immunopathology of upper gastrointestinal acute graft-versus-host disease. Lymphoid cells and endothelial adhesion molecules. Transplantation. 55:572-578.
29. + T cell clones secrete the Th1 pattern of cytokines. J.Immunol. 144:1744-1752.
30. + T cells activated in a graft-versus-host reaction. J.Immunol. 145:2167-2176.
31. Braun, M. Y., B. Lowin, L. French, H. Acha-Orbea, and J. Tschopp. 1996. Cytotoxic T cells deficient in both functional fas ligand and perform show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease. J Exp Med 183:657-661.
32. Antin, J. H., and J. L. Ferrara. 1992. Cytokine dysregulation and acute graft-versus-host disease. Blood. 80:2964-2968.
33. Nestel, F. P., K. S. Price, T. A. Seemayer, and W. S. Lapp. 1992. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease. J.Exp.Med. 175:405-413.
34. Piguet, P. F., G. E. Grau, B. Allet, and P. Vassalli. 1987. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease. J.Exp.Med. 166:1280-1289.
35. Shalaby, M. R., B. Fendly, K. C. Sheehan, R. D. Schreiber, and A. J. Ammann. 1989. Prevention of the graft-versus-host reaction in newborn mice by antibodies to tumor necrosis factor-alpha. Transplantation. 47:1057-1061.
36. Holler, E., H. J. Kolb, A. Moller, J. Kempeni, S. Liesenfeld, H. Pechumer, W. Lehmacher, G. Ruckdeschel, B. Gleixner, and C. Riedner. 1990. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation [see comments]. Blood. 75:1011-1016.
37. Holler, E., H. J. Kolb, and W. Wilmanns. 1993. Treatment of GVHD-TNF-α antibodies and related antagonists. Bone.Marrow. Transplant. 12 Suppl 3:S29-S31.
38. Abhyankar, S., D. G. Gilliland, and J. L. Ferrara. 1993. Interleukin-1 is a critical effector molecule during cytokine dysregulation in graft versus host disease to minor histocompatibility antigens. Transplantation. 56:1518-1523.
39. McCarthy, P. L., Jr., S. Abhyankar, S. Neben, G. Newman, C. Sieff, R. C. Thompson, S. J. Burakoff, and J. L. Ferrara. 1991. Inhibition of interleukin-1 by an interleukin-l receptor antagonist prevents graft-versus-host disease. Blood. 78:1915-1918.
40. Schwaighofer, H., G. Oberhuber, H. Hebart, H. Einsele, M. Herold, D. Nachbaur, B. Eibl, H. Tilg, G. Kropshofer, J. L. Ferrara, and D. Niederwieser. 1997. Endogenous interleukin 1 receptor antagonist during human bone marrow transplantation: increased levels during graft-versus-host disease, during infectious complications, and after immunoglobulin therapy. Transplantation 63:52-56.
41. + lymphoid engraftment. J.Immunol. 152:1004-1013.
42. Fowler, D. H., K. Kurasawa, R. Smith, M. A. Eckhaus, and R. E. Gress. 1994. Donor CD4-enriched Cells of Th2 Cytokine Phenotype Regulate Graft-versus-Host Disease Without Impairing Allogencic Engraftment in Sublethally Irradiated Mice. Blood. 84 [9]:3540-3549.
43. Krenger, W., K. R. Cooke, J. M. Crawford, S. T. Sonis, R. Simmons, L. Pan, J. Delmonte, Jr., M. Karandikar, and J. L. Ferrara. 1996. Transplantation of polarized type 2 donor T cells reduces mortality caused by experimental graft-versus-host disease. Transplantation 62:1278-1285.
44. Fowler, D. H., and R. E. Gress. 1996. GVHD as a Th1-type process: Regulation by cells of Th2 cytokine phenotype. In Graft-vs-Host Disease: Immunology, Pathophysiology, and Treatment. S. Burakoff, H. J. Deeg, J. Ferrara, and K. Atkinson, eds. Marcel Decker, Inc., New York, p. [in-press].
45. + Tel and Tc2 Populations in GVL and GVHD. J.Immunol 157:4811-4821.
46. +, Tc1/Tc2 Populations in Murine GVL: Type I cells generate GVL, Type II cells abrogate GVL. Biology of Blood and Marrow Transplantation 2:118-125.
47. Carlesso, N., J. D. Griffin, and B. J. Druker. 1994. Use of a temperature-sensitive mutant to define the biological effects of the p210BCR-ABL tyrosine kinase on proliferation of a factor-dependent murine myeloid cell line. Oncogene. 9:149-156.
48. + T cells from T cell receptor transgenic mice. J.Exp.Med. 176:1091-1098.
49. + T cells to enhance priming for interferon gamma production and diminishes interleukin 4 inhibition of such priming. Proc.Natl.Acad.Sci. U.S.A. 90:10188-10192.
50. Bradley, L. M., K. Yoshimoto, and S. L. Swain. 1995. The cytokines IL-4, IFN-gamma, and IL-12 regulate the development of subsets of memory effector helper T cells in Vitro. J Immunol. 155:1713-1724.
51. Reisner, Y., I. Ben-Bassat, D. Douer, A. Kaploon, E. Schwartz, and B. Ramot. 1986. Demonstration of clonable alloreactive host T cells in a primate model for bone marrow transplantation. Proc.Natl.Acad.Sci U.S.A. 83:4012-4015.
52. Ferrara, J. L., and H. J. Deeg. 1991. Graft-versus-host disease [see comments]. N.Engl.J.Med. 324:667-674.
53. Aversa, F., A. Terenzi, A. Tabilio, A. Velardi, F. Falzetti, R. Felicini, A. Carotti, L. Ruggeri, Y. Reisner, and M. F. Martelli. 1996. Addition of PBPCs to the marrow inoculum allows engraftment of mismatched T cell-depleted transplants for acute leukemia. Bone.Marrow Transplant 17 Suppl 2:S58-S61.
54. Martin, P. J. 1993. Donor CDS cells prevent allogeneic marrow graft rejection in mice: potential implications for marrow transplantation in humans. J.Exp.Med. 178:703-712.
55. Fink, P. J., R. P. Shimonkevitz, and M. J. Bevan. 1988. Veto cells. Annu.Rev.Immunol. 6:115-137.
56. Hiruma, K., H. Nakamura, P. A. Henkart, and R. E. Gress. 1992. Clonal deletion of postthymic T cells: veto cells kill precursor cytotoxic T lymphocytes. J Exp Med 175:863-868.
57. Martin, P. J. 1996. Prevention of allogeneic marrow graft rejection by donor T cells that do not recognize recipient alloantigens; potential role of a veto mechanism. Blood 88:962-969.
58. Nakamura, H., and R. E. Gress. 1990. Interleukin 2 enhancement of veto suppressor cell function in T-cell-depleted bone marrow in vitro and in vivo. Transplantation. 49:931-937.
59. + T Cells of Tc2 Phenotype Potently Inhibit Marrow Graft Rejection. Blood Manuscript #3-97-10-199:[Winter, 1998 publication].
60. + T Cells of Tc1 and Tc2 Phenotype. 90(5): 2089-2096